BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32211672)

  • 21. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
    Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
    Brancaccio M; Natale F; Falco G; Angrisano T
    Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31877923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma.
    Terasawa H; Kinugasa H; Ako S; Hirai M; Matsushita H; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Kato H; Nouso K; Okada H
    Cancer Biol Ther; 2019; 20(10):1348-1353. PubMed ID: 31328611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
    Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
    Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
    Zhu Y; Wang J; Wang F; Yan Z; Liu G; Ma Y; Zhu W; Li Y; Xie L; Bazhin AV; Guo X
    Biochemistry (Mosc); 2019 May; 84(5):575-582. PubMed ID: 31234772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
    Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
    Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Kriz D; Ansari D; Andersson R
    Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.
    Yang KS; Im H; Hong S; Pergolini I; Del Castillo AF; Wang R; Clardy S; Huang CH; Pille C; Ferrone S; Yang R; Castro CM; Lee H; Del Castillo CF; Weissleder R
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
    Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
    Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
    Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
    Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts.
    Vila-Navarro E; Vila-Casadesús M; Moreira L; Duran-Sanchon S; Sinha R; Ginés À; Fernández-Esparrach G; Miquel R; Cuatrecasas M; Castells A; Lozano JJ; Gironella M
    Ann Surg; 2017 Jun; 265(6):1226-1234. PubMed ID: 27232245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble stroma-related biomarkers of pancreatic cancer.
    Resovi A; Bani MR; Porcu L; Anastasia A; Minoli L; Allavena P; Cappello P; Novelli F; Scarpa A; Morandi E; Falanga A; Torri V; Taraboletti G; Belotti D; Giavazzi R
    EMBO Mol Med; 2018 Aug; 10(8):. PubMed ID: 29941541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.